posted on 2023-03-31, 03:09authored byMohammad Salem, Caroline Wallace, Maria Velegraki, Anqi Li, Ephraim Ansa-Addo, Alessandra Metelli, Hyunwoo Kwon, Brian Riesenberg, Bill Wu, Yongliang Zhang, Silvia Guglietta, Shaoli Sun, Bei Liu, Zihai Li
Lack of GARP Expression by Foxp3+ Treg Cells Does Not Affect the Growth of Subcutaneously Injected MC38 Colon Cancer
Funding
NIH
UPMC
History
ARTICLE ABSTRACT
Activated regulatory T (Treg) cells express the surface receptor glycoprotein-A repetitions predominant (GARP), which binds and activates latent TGFβ. How GARP modulates Treg function in inflammation and cancer remains unclear. Here we demonstrate that loss of GARP in Treg cells leads to spontaneous inflammation with highly activated CD4+ and CD8+ T cells and development of enteritis. Treg cells lacking GARP were unable to suppress pathogenic T-cell responses in multiple models of inflammation, including T-cell transfer colitis. GARP−/− Treg cells were significantly reduced in the gut and exhibited a reduction in CD103 expression, a colon-specific migratory marker. In the colitis-associated colon cancer model, GARP on Treg cells dampened immune surveillance, and mice with GARP−/− Treg cells exhibited improved antitumor immunity. Thus, GARP empowers the functionality of Treg cells and their tissue-specific accumulation, highlighting the importance of cell surface TGFβ in Treg function and GARP as a potential therapeutic target for colorectal cancer therapy.
Significance: These findings uncover functions of membrane-bound TGFβ and GARP that tune the activity of Treg cells, highlighting a potential treatment strategy in autoimmune diseases and cancer.